GC Aesthetics®, a long-established brand in breast aesthetics, and Bimini Health Tech (“Bimini”), a pioneer in novel healthcare solutions, are pleased to announce their groundbreaking Joint Venture partnership aimed at revolutionizing breast reconstruction worldwide.

This strategic collaboration combines GC Aesthetics’ 40 years of experience in design, manufacturing, and distribution of silicone breast Implants with Bimini’s expertise in breast reconstruction innovation, resulting in an unprecedented commitment to providing women with best-in-class solutions for breast reconstruction across the globe, including the USA, LATAM, EMEA, and APAC.

Under the umbrella of the Joint Venture named “OPALINE Aesthetics,” GC Aesthetics will deploy Bimini’s healthcare solutions outside the United States and Canada. Conversely, Bimini will commercialize selective GC Aesthetics’ breast reconstruction solutions in the United States, complementing its industry leading Puregraft® portfolio of technologies that offer a broad set of options to plastic and reconstructive surgeons and their patients.

We want to provide patients around the globe state-of-the-art breast reconstruction solutions with a demonstrated best-in-class safety profile,” said Carlos Reis Pinto, CEO of GC Aesthetics. “The combination of Bimini and GCA portfolios will not only expand patient access to a broader range of solutions, but it will also lead to the development of new technologies which will enhance the standard of care in Breast Reconstruction’, adds Brad Conlan, CEO and co-founder of Bimini Health Tech.

The driving force behind this partnership is a shared passion to provide the most innovative and advanced solutions to patients and plastic surgeons. By joining forces, GC Aesthetics and Bimini Health Tech intend to elevate women’s healthcare and well-being, offering comprehensive support for breast reconstruction needs. Collectively, we will embark on this journey, partnering with medical professionals worldwide.

SOURCEPRNewswire
Previous articleWingderm® Has Unveiled the Latest Research of Mesoskin for Mesotherapy Treatment at AMWC
Next articleAllergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines